STOCK TITAN
  1. Home
  2. News
  3. ILMN

Illumina to Webcast Upcoming Investor Conference Presentations

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.

SVB Leerink Annual Global Healthcare Conference on Thursday, February 25, 2021
Fireside Chat at 12:00pm Pacific Time / 3:00pm Eastern Time

Cowen Annual Health Care Conference on Tuesday, March 2, 2021
Fireside Chat at 9:50am Pacific Time / 12:50pm Eastern Time

The live webcasts can be accessed under the Investor Info section of the "company" tab at www.illumina.com. Replays will be posted on Illumina’s website as soon as possible after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Stock ILMN logo
Illumina, Inc.

NASDAQ:ILMN

ILMN Rankings

#562 Ranked by Market Cap
#4729 Ranked by Stock Gains
N/A Ranked by Dividends

ILMN Latest News

May 15, 2024
Illumina To Webcast Upcoming Investor Conference
May 13, 2024
GRAIL to Host Capital Markets Day
May 6, 2024
Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
May 3, 2024
Illumina To Webcast Upcoming Investor Conference
May 2, 2024
Illumina Reports Financial Results for First Quarter of Fiscal Year 2024

ILMN Stock Data

18.32B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.